Benzinga - On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Gilead Sciences, Inc. (NASDAQ: GILD), which has 7% free cash flow yield and a 3.6% dividend yield. "I think it will continue to be a good name to own this year," she added.
Benzinga's analyst ratings data shows GILD with a Neutral consensus rating.
Morgan Stanley recently maintained Gilead Sciences with an Equal-Weight and raised the price target from $81 to $85.
Josh Brown of Ritholtz Wealth Management named Berkshire Hathaway Inc. (NYSE: BRK-B) (NYSE: BRK-A) as his final trade.
Don’t forget to check out our premarket coverage here
Jim Lebenthal of Cerity Partners said Wynn Resorts, Limited (NASDAQ: WYNN) looks like it’s breaking out right now.
Shares of casino stocks traded higher on Thursday in sympathy with Las Vegas Sands Corp. (NYSE: LVS), which reported better-than-expected quarterly results.
Amy Raskin of Chevy Chase Trust said Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) stock has been in a strong trend.
Vertex recently announced Health Canada market authorization for ORKAMBI in children with cystic fibrosis between ages 1 to less than 2 years of age.
Price Action: Berkshire Hathaway shares rose 0.2% to close at $323.82, while Gilead Sciences gained 0.7% to settle at $84.69 on Thursday. Vertex Pharmaceuticals gained 0.2% to $329.15, while Wynn Resorts added 1.4% to $113.69 during the session.
Check This Out: Citigroup, Dell And 2 Other Stocks Insiders Are Selling
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Read the original article on Benzinga